^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
RNA-FIT assay

Company:
Geneoscopy
Type:
Laboratory Developed Test
Evidence

News

almost2years
Geneoscopy cost-effectiveness modeling data demonstrates potential to reduce colorectal cancer cases and deaths in the United States with RNA-FIT screening test (PRNewswire)
"Geneoscopy Inc...announced findings from an early cost-effectiveness modeling study that aimed to assess the total costs and health outcomes associated with the use of an investigational RNA-FIT biomarker panel versus multi-target stool DNA (mt-sDNA), fecal immunochemical test (FIT), and colonoscopy alone for the screening of colorectal cancer (CRC). Geneoscopy's RNA-FIT test is being evaluated as a potential noninvasive, at-home diagnostic screening test to detect colorectal neoplasms, including advanced adenomas, in average-risk individuals. The data was highlighted in a poster at the 2022 Digestive Disease Week meeting being held in San Diego from May 21-24."
HEOR
|
RNA-FIT assay
almost2years
COST-EFFECTIVENESS ANALYSIS OF A NOVEL RNA-FIT TEST AS A STRATEGY FOR CRC SCREENING IN AN AVERAGE RISK US POPULATION (DDW 2022)
Sensitivity analyses demonstrated that compliance rate, specificity of the RNA-FIT test, cost of the test, and screening interval were critical inputs for the model. Conclusion : The RNA-FIT could serve as a valuable and cost-effective option for colorectal cancer screening strategy in the average risk population.
HEOR • Clinical
|
RNA-FIT assay
over2years
CRC-PREVENT: Clinical validation trial to show expedited and diverse recruitment for the non-invasive RNA-FIT test that can detect advanced colorectal neoplasia with high sensitivity. (ASCO-GI 2022)
Use of a decentralized recruitment strategy permitted highly successful enrollment in the face of challenges associated with COVID-19. With respect to race, ethnicity, socioeconomic status, and geography, all metrics represented significantly more diverse populations than observed in traditional clinical studies. Decentralized enrollment mitigated selection bias, and will result in data more reflective of the intended use population.
Clinical
|
RNA-FIT assay
over3years
[VIRTUAL] Colonosight: Multitarget RNA-FIT assay for noninvasive detection of advanced colorectal neoplasia. (ASCO-GI 2021)
"The RNA-FIT assay demonstrated clinically relevant detection of all advanced neoplasia, including early carcinomas, advanced adenomas, and other precancerous lesions. This assay could represent a noninvasive option to prevent colorectal cancer development through precancerous adenoma detection."
RNA-FIT assay